Roxybond (Oxycodone HCl) Patent Expiration, LOE Window & CMS Spending

Roxybond (Oxycodone HCl) by Protega: FDA Orange Book LOE 2028-08-12, 11 AB generics, $3.0M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorProtega
FDA Application & PathwayN209777 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-08-12
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$3.0M
2024 Medicare Part D Spend$2.2M
2024 Medicaid Spend$783K
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 32.9% 2-yr change)